Euro OTC Market Reports

7 April 1997

The European consumer health care market will grow more than 150% to$42.5 billion by 2006, forecasts PROMAR International. Of this, the over-the-counter sector will account for around $21 billion, growing 35% in the period.

By 2006, it says, the OTC sector will be operating in a deregulated marketplace, and for an industry hitherto protected from the full impact of market forces, the consequences will be enormous.

- The UK OTC market is Europe's third largest, at a value of around $1.35 billion, and its growth is due in part to UK regulators' liberal and progressive attitude towards OTCs, says a Datamonitor study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight